Dashboard
Manage Tickers

IDYA IDEAYA Biosciences, Inc.

Nasdaq ideayabio.com


$ 32.58 $ 0.00 (0 %)    

Tuesday, 28-Oct-2025 11:39:36 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 630.13 $ 0.00 (0 %)
DIA $ 477.20 $ 0.00 (0 %)
SPY $ 685.36 $ 0.00 (0 %)
TLT $ 92.12 $ 0.00 (0 %)
GLD $ 364.74 $ 0.00 (0 %)
$ 32.37
$ 32.50
$ 32.43 x 400
$ 32.68 x 41
$ 32.50 - $ 33.63
$ 13.45 - $ 32.67
2,058,502
na
2.84B
$ 0.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-18-2025 12-31-2024 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-20-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-07-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-23-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-24-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-maintains-overweight-on-ideaya-biosciences-raises-price-target-to-79
JP Morgan Maintains Overweight on IDEAYA B...
10/23/2025 15:53:36

JP Morgan analyst Anupam Rama maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and raises the price target from ...

goldman-sachs-maintains-neutral-on-ideaya-biosciences-raises-price-target-to-30
Goldman Sachs Maintains Neutral on IDEAYA ...
10/21/2025 18:01:49

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Neutral and raises the price target ...

slb-to-rally-around-44-here-are-10-top-analyst-forecasts-for-tuesday
SLB To Rally Around 44%? Here Are 10 Top A...
10/21/2025 13:02:06

rbc-capital-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-41
RBC Capital Maintains Outperform on IDEAYA...
10/21/2025 12:09:40

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target...

btig-reiterates-buy-on-ideaya-biosciences-maintains-62-price-target
BTIG Reiterates Buy on IDEAYA Biosciences,...
10/21/2025 10:11:12

BTIG analyst Justin Zelin reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and maintains $62 price target.

ideaya-biosciences-presents-positive-clinical-data-from-ongoing-phase-2-optimum-09-trial-of-neoadjuvant-darovasertib-in-patients-with-primary-uveal-melanoma
IDEAYA Biosciences Presents Positive Clini...
10/20/2025 10:34:54

83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage57% (24/42) eye pre...

ideaya-biosciences-reports-median-overall-survival-results-from-phase-12-trial-optimum-01-of-darovasertib-in-combination-with-pfizers-crizotinib1x-for-metastatic-uveal-melanoma
Ideaya Biosciences Reports Median Overall ...
10/20/2025 10:12:50

Combination demonstrated median overall survival (OS) of 21.1 months, compared to reported historical mOS of approximately 12 m...

guggenheim-initiates-coverage-on-ideaya-biosciences-with-buy-rating-announces-price-target-of-50
Guggenheim Initiates Coverage On IDEAYA Bi...
09/18/2025 13:00:12

Guggenheim analyst Paul Jeng initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Buy rating and announces Price Ta...

buying-ideaya-might-be-the-wrong-idya-right-now
Buying IDEAYA Might Be The Wrong IDYA Righ...
09/16/2025 11:01:43

IDEAYA Stock's Adhishthana.com cycle signals prolonged weakness after a failed Cakra, with underperformance likely until Ma...

mizuho-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-44
Mizuho Maintains Outperform on IDEAYA Bios...
09/12/2025 14:04:16

Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target fr...

alibaba-to-rally-around-35-here-are-10-top-analyst-forecasts-for-tuesday
Alibaba To Rally Around 35%? Here Are 10 T...
09/09/2025 14:11:09

rbc-capital-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-38
RBC Capital Maintains Outperform on IDEAYA...
09/09/2025 13:25:57

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target...

cantor-fitzgerald-reiterates-overweight-on-ideaya-biosciencesto-overweight
Cantor Fitzgerald Reiterates Overweight on...
09/09/2025 13:15:58

Cantor Fitzgerald analyst Li Watsek reiterates IDEAYA Biosciences (NASDAQ:IDYA) from Overweight to Overweight.

stephens--co-reiterates-overweight-on-ideaya-biosciences-maintains-45-price-target
Stephens & Co. Reiterates Overweight on ID...
09/09/2025 13:11:34

Stephens & Co. analyst Sudan Loganathan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and maintains $45 ...

jmp-securities-maintains-market-outperform-on-ideaya-biosciences-raises-price-target-to-45
JMP Securities Maintains Market Outperform...
09/08/2025 14:10:24

JMP Securities analyst Silvan Tuerkcan maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform and raises the pr...

ideaya-biosciences-reports-data-from-phase-12-combination-trial-of-ide397-and-trodelvy-in-mtap-deletion-urothelial-cancer
IDEAYA Biosciences Reports Data From Phase...
09/08/2025 12:07:50

Overall response rate (ORR) of 57% (4/7; 3cPR+1uPR) in patients treated with a combination of 30 mg IDE397 plus 7.5mg/kg Trodel...

ideaya-biosciences-reports-tumor-shrinkage-and-vision-gains-in-eye-cancer-trial
IDEAYA Biosciences Reports Tumor Shrinkage...
09/08/2025 10:03:07

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, will present positive interim data at th...

ideaya-biosciences-and-hengrui-pharma-presented-initial-data-from-hengruis-phase-1-trial-of-ide849-shr-4849-at-the-iaslc-2025-world-conference-on-lung-cancer
Ideaya Biosciences And Hengrui Pharma Pres...
09/07/2025 17:21:25

80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending conf...

jmp-securities-initiates-coverage-on-ideaya-biosciences-with-market-outperform-rating-announces-price-target-of-41
JMP Securities Initiates Coverage On IDEAY...
09/04/2025 12:33:54

JMP Securities analyst Silvan Tuerkcan initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform ratin...

barclays-initiates-coverage-on-ideaya-biosciences-with-overweight-rating-announces-price-target-of-40
Barclays Initiates Coverage On IDEAYA Bios...
09/04/2025 10:49:04

Barclays analyst Peter Lawson initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight rating and announces ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION